Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Parmax PharmaBOM:540359 +0.98%42 EBITDA Margin % is 35.37% as of Jun. 2026, which is 273% above its 10-year median of 9.49. GuruFocus rates BOM:540359 with a GF Score™ of 42/100 and a GF Value™ of ₹40.73 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 960 Drug Manufacturers companies, Parmax Pharma ranks worse than 75.31% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Parmax Pharma's EBITDA for the
three
months ended in Jun. 2026 was ₹29.1 Mil. Parmax Pharma's Revenue for the
three
months ended in Jun. 2026 was ₹82.2 Mil. Therefore, Parmax Pharma's EBITDA margin for the quarter that ended in Jun. 2026 was 35.37%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Parmax Pharma EBITDA Margin % Related Terms
Parmax Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Parmax Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Parmax Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Parmax Pharma EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Parmax Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Parmax Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parmax Pharma (BOM:540359) has a EBITDA Margin % of 35.37% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Parmax Pharma and its competitors. This is 273% above median its historical median of 9.49. According to the industry distribution chart, Parmax Pharma ranks #723 out of 960 companies in the Drug Manufacturers industry, placing it in the top 75.3%.
Is Parmax Pharma's EBITDA Margin % too high?
Parmax Pharma's current EBITDA Margin % of 35.37% is 273% above median its 10-year median of 9.49. The Drug Manufacturers industry median EBITDA Margin % is 11.89. Parmax Pharma's value of 35.37% is 197.6% above this industry median. Based on the distribution chart, Parmax Pharma ranks #723 out of 960 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Parmax Pharma has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Parmax Pharma's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Parmax Pharma ranks #723 out of 960 companies for EBITDA Margin %. This places Parmax Pharma in the lower half of its industry. The industry median EBITDA Margin % is 11.89. Parmax Pharma's value of 35.37% is 197.6% above this benchmark. While the company's 10-year median is 9.49 vs. the industry median of 11.89, Parmax Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 11.89, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Parmax Pharma's current EBITDA Margin % of 35.37% is 197.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Parmax Pharma and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 11.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Parmax Pharma's current EBITDA Margin % is 35.37%, which is 273% above median its own 10-year median of 9.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parmax Pharma stock overvalued right now?
Based on GuruFocus' analysis, Parmax Pharma (BOM:540359) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹40.73, compared to a current price of ₹133.75 — trading 228.4% above its estimated fair value. The current EBITDA Margin % is 35.37%, which is 273% above median its 10-year median of 9.49 and 197.6% above the Drug Manufacturers industry median of 11.89. Parmax Pharma's overall GF Score™ is 42/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Parmax Pharma (BOM:540359), the current EBITDA Margin % is 35.37% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Parmax Pharma (BOM:540359) Overvalued in 2026?
Based on GuruFocus' analysis, Parmax Pharma stock appears to be overvalued.
The current stock price of ₹133.75 is trading 228.4% above its estimated GF Value™ of ₹40.73.
GuruFocus considers Parmax Pharma to be Significantly Overvalued.
Key valuation signals for BOM:540359:
EBITDA Margin %: 35.37% (273% above median its 10-year median of 9.49)
GF Value™: ₹40.73 vs. price of ₹133.75 (228.4% above fair value)
Industry Position: 197.6% above the Drug Manufacturers median (#723 of 960)
No single metric tells the full story. See the BOM:540359 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540359 has been successfully added to your 
